In a phase 1/2 clinical trial (NCT04351022), four out of six AML patients treated with CD38 CAR-T cells achieved CR, the median of 7.9 months, with no severe adverse events (CTCAE v4.0) [109] (Fig. 2). The gene discussed is CD38; the disease is acute myeloid leukemia.